Cardiovascular toxicity associated with adjuvant trastuzumab therapy: Prevalence, patient characteristics, and risk factors

Therapeutic Advances in Drug Safety

Volumn 5, Issue 4, 2014, Pages 154-166

  Onitilo, Adedayo A ^a   Engel, Jessica M ^a   Stankowski, Rachel V ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

breast cancer; doxorubicin; epidermal growth factor; heart failure; oxidative stress; trastuzumab

Indexed keywords

AFATINIB; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; NERATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; REACTIVE OXYGEN METABOLITE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ALCOHOL CONSUMPTION; ASYMPTOMATIC DISEASE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR TOXICITY; DETERIORATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SAFETY; ECHOCARDIOGRAPHY; GENETIC RISK; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); OXIDATIVE STRESS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84903511802     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614529603     Document Type: Review

References (74)

1. Addolorato G. Leggio L. Ojetti V. Capristo E. Gasbarrini G. Gasbarrini A. (2008) Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. Appetite 50: 50–56.
2. Allen L. Yood M. Wagner E. Aiello Bowles E. Pardee R. Wellman R. (2012) Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care 25 May (Epub ahead of print).
3. American Cancer Society (2013) What are the key statistics about breast cancer in men? American Cancer Society. Available at: http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-key-statistics (accessed 18 July 2013).
4. Barth A. Zhang Y. Li T. Smith R. Chimenti I. Terrovitis I. (2012) Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab. Stem Cells Transl Med 1 289–297.
5. Beauclair S. Formento P. Fischel J. Lescaut W. Largillier R. Chamorey E. (2007) Role of the HER2 [Ile655Val] genetic polymorphism in tumorigenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol 18: 1335–1341.
6. Berry D. Cronin K. Plevritis S. Fryback D. Clarke L. Zelen M. (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353: 1784–1792.
7. Bilous M. Ades C. Armes J. Bishop J. Brown R. Cooke B. (2003) Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 12: 92–98.
8. Binkley J. Harris S. Levangie P. Pearl M. Guglielmino J. Kraus V. (2012) Patient perspectives on breast cancer treatment side effects and the prospective surveillance model for physical rehabilitation for women with breast cancer. Cancer 118: 2207–2216.
9. Bittner B. Richter W. Hourcade-Potelleret F. McIntyre C. Herting F Zepeda M. (2012) Development of a subcutaneous formulation for trastuzumab – nonclinical and clinical bridging approach to the approved intravenous dosing regimen. Arzneinmitelforschung 62: 401–409.
10. Bondia-Pons I. Ryan L. Martinez J. (2012) Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem 68: 701–711.
11. Bowles E. Wellman R. Feigelson H. Onitilo A. Freedman A. Delate T. (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104: 1293–1305.
12. Braden A. Stankowski R. Engel J. Onitilo A. (2013) Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des 25 November (Epub ahead of print).
13. Brem S. Kumar N. (2011) Management of treatment-related symptoms in patients with breast cancer. Clin J Oncol Nurs 15: 63–71.
14. Buzdar A. Ibrahim N. Francis D. Booser D. Thomas E. Theriault R. (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676–3685.
15. Cardinale P. Colombo A. Tomisi R. Sandri M. Civelli M. Salvatici M. (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28: 3910–3916.
16. Carmona-Bayonas A. (2007) Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 16: 323–325.
17. Chien A. Rugo H. (2010) The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 9: 335–346.
18. Cochet A. Quilichini G. Dygai-Cochet I. Touzery C. Toubeau M. Berriolo-Riedinger A. (2011) Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 130: 845–854.
19. Costa R Kurra G. Greenberg L. Geyer C. (2010) Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 21: 2153–2160.
20. Coughlin S. Ekwueme D. (2009) Breast cancer as a global health concern. Cancer Epidemiol 33: 315–318.
21. De Keulenaer G. Doggen K. Lemmens K. (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106: 35–46.
22. Dent S. Hopkins S. Graham N. Johnson C. Law A. Campbell M. (2012) The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract 2012: 135819.
23. Diéras V. Bachelot T. (2013) The success story of trastuzumab emtansine, a target therapy in HER2-positive breast cancer. Target Oncol 14 July (Epub ahead of print).
24. Ewer S. Ewer M. (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31: 459–467.
25. Ewer M. Vooletich M. Durand J. Woods M. Davis J. Valero V. (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820–7826.
26. Farolfi A. Melegari E. Aquilina M. Scarpi E. Ibrahim T. Maltoni R. (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99: 634–639.
27. Genetech, Inc. (2003) Package Insert, herceptin (Trastuzumab). Food and Drug Administration. Available at: http://www.accessdata.fd.gov/drugsatfda_docs/label/2000/trasgen020900lb.htm (Accessed 30 July 2013).
28. Gianni L. Dafni U. Delber R. Azambuja E. Muelbauer S. Goldhirsch A. (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12: 236–244.
29. Gianni L. Eiermann W. Semiglazov V. Manikhas A. Lluch A. Tjulandin S. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377–384.
30. Go A. Lee W. Yang J. Lo J. Gurwitz J. (2006) Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 296: 2105–2111.
31. Heck S. Gulati G. Ree A. Schulz-Menger J. Gravdehaug B. Røsjø H. (2012) Rationale and design of the prevention of cardiac dysfunction during an adjuvant breast cancer therapy (PRADA) trial. Cardiology 123: 240–247.
32. Incorvati J. Shah S. Mu Y. Lu J. (2013) Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 6: 38.
33. Ismael G. Hegg R. Muehlbauer S. Heinsmann D. Lum B. Kim S. (2012) Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicenter, randomised trial. Lancet Oncol 13: 869–878.
34. Jensen B. McLeod H. (2013) Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 14: 205–213.
35. Joensuu H. Kellokumpu-Lehtinen P. Bono P. Alanko T. Kataja V. Asola R. (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 23: 809–820.
36. Joensuu H. Kellokumpu-Lehtinen P. Huovinen R. Jukkola-Vuorinen A. Tanner M. Kokko R. (2014) Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncol 53: 186–194.
37. Kalam K. Marwick T. (2013) Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur J Cancer 49; 2900–2909.
38. Lemieux J. Diorio C. Côté M. Provencher L. Barabé F. Jacob S. (2013) Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab. Anticancer Res 33: 2569–2576.
39. Moja L. Tagliabue L. Balduzzi S. Parmelli E. Pistotti V. Guarneri V. (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4: CD006243.
40. Naumann D. Rusius V. Margiotta C. Nevill A. Carmichael A. Rea D. (2013) Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 33: 1717–1720.
41. Onami S. Ozaki M. Mortimer J. Pal S. (2012) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65: 308–314.
42. Onitilo A. Engel J. Glurich I. Stankowski R. Williams G. Doi S. (2012a) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control 23: 991–1008.
43. Onitilo A. Engel J. Stankowski R. Liang H. Berg R. Doi S. (2012b) High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 134: 291–298.
44. Oreto L. Todaro M. Umland M. Kramer C. Qamar R. Carej S. (2012) Use of echocardiography to evaluate the cardiac effects of therapies used in cancer treatment: what do we know? J Am Soc Echocardiogr 25: 1141–1152.
45. Perez E. Morgan J. (2013) Cardiotoxicity of trastuzumab and other HER2-targeted agents. UpToDate. Available at: http://www.uptodate.com/contents/cardiotoxicity-of-trastuzumab-and-other-her2-targeted-agents (accessed 18 July 2013).
46. Perez E. Suman V. Davidson N. Sledge G. Kaufman P. Hudis C. (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26: 1231–1238.
47. Piotrowski G. Gawor R. Stasiak A. Gawor Z. Potemski P. Banach M. (2012) Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 ∑ a prospective study. Arch Med Sci 8: 227–235.
48. Procter M. Suter T. de Azambuja E. Dafni U. van Dooren V. Muehlbauer S. (2010) Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J Clin Oncol 28: 3422–3428.
49. Rastogi P. Jeong J. Geyer C. Costantino J. Romond E. Ewer M. (2007) Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)↑paclitaxel (T) vs. AC↑T with trastuzumab (H). J Clin Oncol 25: LBA513.
50. Romond E. Perez E Bryant J. Suman V. Geyer C. Jr Davidson N. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673–1684.
51. Russo G. Cioffi G. Di Lenarda A. Tuccia F. Bovelli D. Di Tano G. (2012) Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. Intern Emerg Med 7: 439–446.
52. Sawaki M. Tukodome N. Mizuno T. Nakayama T. Taira N. Bando H. (2011) Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. Jpn J Clin Oncol 41: 709–712.
53. Schneeweiss A. Chia S. Hickish T. Harvey V. Eniu A. Hegg R. (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24: 2278–2284.
54. Seicean S. Seicean A. Alan N. Plana J. Budd G. Marwick T. (2013) Cardioprotective effect of β-adrenoreceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail 6: 420–426.
55. Seidman A. Hudis C. Pierri M. Shak S. Paton V. Ashby M. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–1221.
56. Sendur M. Aksoy S. Altundag K. (2013) Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29: 1015–1024.
57. Serrano C. Cortés J. De Mattos-Arruda L. Bellet M. Gómez P. Saura C. (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23: 897–902.
58. Siegel R. DeSantis C. Virgo K. Stein K. Mariotto A. Smith T. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220–241.
59. Slamon D. Clark G. Wong S. Levin W. Ullrich A. McGuire W. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182.
60. Slamon D. Eiermann W. Robert N. Pienkowski T. Martin M. Press M. (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273–1283.
61. Smith I. Procter M. Gelber R. Guillaume S. Feyereislova A. Dowsett M. (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369: 29–36.
62. Spielmann M. Roché H. Delozier T. Canon J. Romieu G. Bourgeois H. (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27: 6129–6134.
63. Tan-Chiu E. Yothers G. Romond E. Geyer C. Ewer M. Keefe D. (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811–7819.
64. Tanz R. Mahfoud T. Bazine A. Khmamouch R. Bensouda Y. Ismaili N. (2011) Cardiac safety of trastuzumab in adjuvant: a review across 53 observations [Article in French]. J Gynecol Obstet Biol Reprod (Paris) 40: 144–148.
65. Tarantini L. Cioffi G. Gori S. Tuccia F. Boccardi L. Bovelli D. (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18: 113–119.
66. Telli M. Hunt S. Carlson R. Guardino A. (2007) Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 25: 3525–3533.
67. Telli M. Witteles R. (2011) Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw 9: 243–249.
68. Tocchetti C. Ragone G. Coppola C. Rea D. Piscopo G. Scala S. (2012) Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur J Heart Fail 14: 130–137.
69. Toomey P. Vohra N. Ghansah T. Sarnaik A. Pilon-Thomas S. (2013) Immunotherapy for gastrointestinal malignancies. Cancer Control 20: 32–42.
70. Tripathy D. Slamon D. Cobleigh M. Arnold A. Saleh M. Mortimer J. (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 22: 1063–1070.
71. Verma S. Lavasani S. Mackey J. Pritchard K. Clemons M. Dent S. (2010) Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol 17: 20–33.
72. Viani G. Afonso S. Stefano E. De Fendi L. Soares F. (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7: 153.
73. Wu D. Zhai Q. Shi X. (2006) Alcohol-induced oxidative stress and cell response. J Gastroenterol Hepatol 21: S26–S29.
74. Zeglinski M. Ludke A. Jassal D. Singal P. (2011) Trastuzumab-induced cardiac dysfunction: a ‘dual-hit–. Exp Clin Cardiol 16: 70–74.